Hôpital Maisonneuve-Rosemont is a hospital in Montreal, Quebec, Canada, located in the boroughs of Rosemont–La Petite-Patrie and Mercier-Hochelaga-Maisonneuve. It serves the eastern part of the city and offers 800 beds. It employs 5,000 people and 3,000 students annually.

There are 800 beds in CIUSSS de l'Est de l'Île de Montréal.

During the past decade, CIUSSS de l'Est de l'Île de Montréal conducted 72 clinical trials. In the 10-year time frame, 72 clinical trials started and 11 clinical trials were completed, i.e. on average, 15.3% percent of trials that started reached the finish line to date. In the past 5 years, 39 clinical trials started and 9 clinical trials were completed. i.e. 23.1% of trials that started reached the finish line.

Out of the total clinical trials conducted in "CIUSSS de l'Est de l'Île de Montréal" #1 sponsor was "Ciusss de L'Est de l'Île de Montréal" with 23 trials, followed by "Celgene" with 6 trials sponsored, "Canadian Cancer Trials Group" with 5 trials sponsored, "Janssen Research & Development, LLC" with 5 trials sponsored and "Eli Lilly and Company" with 5 trials sponsored. Other sponsors include 31 different institutions and companies that sponsored additional 30 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "CIUSSS de l'Est de l'Île de Montréal" #1 collaborator was "Medasense Biometrics Ltd" with 3 trials as a collaborator, "Merck Sharp & Dohme LLC" with 3 trials as a collaborator, "ExCellThera inc." with 2 trials as a collaborator, "Acceleron Pharma Inc. (a wholly owned subsidiary of Merck Sharp and Dohme, a subsidiary of Merck & Co., Inc.)" with 1 trials as a collaborator and "Advance Dosage Forms, Inc." with 1 trials as a collaborator. Other collaborators include 45 different institutions and companies that were collaborators in the rest 55 trials.

According to Clinical.Site data, the most researched conditions in "CIUSSS de l'Est de l'Île de Montréal" are "Anesthesia" (8 trials), "Multiple Myeloma" (6 trials), "Crohn's Disease" (3 trials), "Nociceptive Pain" (3 trials) and "Breast Cancer" (2 trials). Many other conditions were trialed in "CIUSSS de l'Est de l'Île de Montréal" in a lesser frequency.

Most popular intervention types in "CIUSSS de l'Est de l'Île de Montréal" are "Drug" (47 trials), "Procedure" (10 trials), "Biological" (9 trials), "Other" (9 trials) and "Device" (8 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (15 trials), "Dexamethasone" (5 trials), "Pembrolizumab" (5 trials), "Bortezomib" (3 trials) and "Carfilzomib" (3 trials). Other intervention names were less common.

The vast majority of trials in "CIUSSS de l'Est de l'Île de Montréal" are 67 trials for "All" genders, 8 trials for "Female" genders and 3 trials for "Male" genders.

Currently, there are NaN active trials in "CIUSSS de l'Est de l'Île de Montréal". 1 are not yet recruiting, 30 are recruiting, 15 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 20 completed trials in CIUSSS de l'Est de l'Île de Montréal, undefined suspended trials, and 8 terminated clinical trials to date.

Out of the total trials that were conducted in CIUSSS de l'Est de l'Île de Montréal, 4 "Phase 1" clinical trials were conducted, 13 "Phase 2" clinical trials and 29 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 7 trials, and there were also 19 trials that are defined as “Not Applicable".